171) Patients were monitored for blood sugar levels, serum C-peptide levels, glycosylated hemoglobin (Hb1Ac) and glutamic acid decarboxylase (GAD) antibodies. |
PMID:24317657 DOI:10.1007/s10238-013-0266-1 |
2015 Clinical and experimental medicine |
* Novel therapy for insulin-dependent diabetes mellitus: infusion of in vitro-generated insulin-secreting cells. |
- Insulin-dependent diabetes mellitus (IDDM) is a metabolic disease usually resulting from autoimmune-mediated β-cell destruction requiring lifetime exogenous insulin replacement. Mesenchymal stem cells (MSC) hold promising therapy. We present our experience of treating IDDM with co-infusion of in vitro autologous adipose tissue-derived MSC-differentiated insulin-secreting cells (ISC) with hematopoietic stem cells (HSC). This was an Institutional Review Board approved prospective non-randomized open-labeled clinical trial after informed consent from ten patients. ISC were differentiated from autologous adipose tissue-derived MSC and were infused with bone marrow-derived HSC in portal, thymic circulation by mini-laparotomy and in subcutaneous circulation. Patients were monitored for blood sugar levels, serum C-peptide levels, glycosylated hemoglobin (Hb1Ac) and glutamic acid decarboxylase (GAD) antibodies. Insulin administration was made on sliding scale with an objective of maintaining FBS < 150 mg/dL and PPBS around 200 mg/dL. Mean 3.34 mL cell inoculums with 5.25 × 10(4) cells/μL were infused. No untoward effects were observed. Over a mean follow-up of 31.71 months, mean serum C-peptide of 0.22 ng/mL before infusion had sustained rise of 0.92 ng/mL with decreased exogenous insulin requirement from 63.9 international units (IU)/day to 38.6 IU/day. Improvement in mean Hb1Ac was observed from 10.99 to 6.72%. Mean GAD antibodies were positive in all patients with mean of 331.10 IU/mL, which decreased to mean of 123 IU/mL. Co-infusion of autologous ISC with HSC represents a viable novel therapeutic option for IDDM. |
(1)29 and | (20)4 treatment | (39)2 (FA) | (58)2 from |
(2)15 *null* | (21)3 (AA) | (40)2 (PA) | (59)2 hydrolysis |
(3)11 in | (22)3 (ALA) | (41)2 (PLGA) | (60)2 interactions |
(4)10 phenethyl | (23)3 (GABA) | (42)2 (PLGA), | (61)2 may |
(5)10 phosphatase | (24)3 (NEFA) | (43)2 (SA) | (62)2 nanoparticles |
(6)9 is | (25)3 changes | (44)2 (SLA) | (63)2 peptide |
(7)8 was | (26)3 decarboxylase | (45)2 (TA) | (64)2 proteins |
(8)6 (HA) | (27)3 etching | (46)2 (TCA) | (65)2 racemization |
(9)6 reactive | (28)3 levels | (47)2 A | (66)2 ratio |
(10)5 as | (29)3 metabolism | (48)2 BSA | (67)2 residues |
(11)5 bacteria | (30)3 on | (49)2 Ig-superfamily | (68)2 substances |
(12)5 group | (31)3 protein | (50)2 Schiff | (69)2 suppressive |
(13)5 or | (32)3 sequence | (51)2 biosynthesis | (70)2 synthetase |
(14)5 synthesis | (33)3 sequences | (52)2 by | (71)2 the |
(15)5 to | (34)3 status | (53)2 changes, | (72)2 therapy |
(16)4 binding | (35)3 were | (54)2 composition | (73)2 vitamin |
(17)4 derivatives | (36)2 (DHA) | (55)2 contents | |
(18)4 for | (37)2 (EDTA) | (56)2 cycle | |
(19)4 solution | (38)2 (EPA) | (57)2 extract |
add keyword